STA
LXRX icon

Summit Trail Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Summit Trail Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,520
Closed -$16K – 1151
2017
Q4 		$16K Buy
+1,520
New +$15.8K ﹤0.01% 1105

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Summit Trail Advisors's LXRX Position: Q1 2018 in Review

Summit Trail Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2018, closing a stake of 1,520 shares — an estimated $16K sold.

Summit Trail Advisors first reported a position in LXRX in Q4 2017 and held it in 1 quarter. The position peaked at $16K in Q4 2017. 126 funds tracked by Wall St. Rank hold LXRX as of Q1 2018.

  • Summit Trail Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 1,520 Lexicon Pharmaceuticals shares in Q1 2018, an estimated $16K.
  • Summit Trail Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Lexicon Pharmaceuticals position peaked at $16K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.